The investigators grouped patients in the positive MRD cohort with different types of response together, making it difficult to directly compare MRD status between de novo CML-BP and Ph-positive ALL.

Explore the evolving treatment landscape of chronic myeloid leukemia with asciminib, a promising new TKI showing high ...

The meta-analysis developed sense of the pooled effect this factor had on survival, indicating that patients with MRD negative status experienced a 20% reduced risk of death compared with patients ...

Emilie Aschenbrenner, PharmD, BCOP, highlights how measurable residual disease (MRD) testing can support value-based care in ...

In a Children’s Oncology Group-led study of pediatric patients with acute lymphoblastic leukemia (ALL), evidence from the largest analysis to date comparing bone marrow MRD assessment to ...

Findings showed 30% of patients in the ponatinib arm achieved MRD-negative CR rate at the end of the induction phase compared with 12% of those in the imatinib arm (risk difference, 0.18 [95% CI ...

Advances in tyrosine kinase inhibitors yielded robust options for CML, raising questions about US accelerated approval for the frontline use of asciminib in this indication.

Disclosures Clin Lymphoma Myeloma. 2009;9 (4) In This Article Abstract and Introduction Acute Myelogenous Leukemia of the Elderly is Intrinsically More Resistant to Therapy Influence of Clinical ...